health

The biggest practical shift this month is the first five-year durability data for focused ultrasound (FUS) subthalamotomy — a procedure that uses precisely aimed sound waves to permanently ablate a small target in the subthalamic nucleus, relieving tremor and motor fluctuations without implanted hardware. A five-year follow-up study now shows that a meaningful share of patients retain clinically significant motor benefit at five years, though the effect erodes over time and the procedure remains unilateral (one side of the brain only), limiting its usefulness for people with bilateral symptoms. This is the longest durability window published specifically for FUS subthalamotomy, and it sharpens the choice conversation: FUS requires no implanted hardware and carries a short recovery, but it is irreversible and cannot be adjusted afterward. A concurrent comprehensive review maps FUS's expanding uses — including experimental blood-brain-barrier opening for drug delivery — noting that the technology is moving faster than the evidence base for its newer applications. For anyone currently weighing surgical options, the five-year data is now the reference point: ask your movement disorder specialist how your symptom profile and age compare to the cohort studied.

DBS: clearer on speech, closer to self-optimising

Deep brain stimulation of the subthalamic nucleus (STN-DBS) remains the most established surgical option for motor fluctuations, but its effect on speech has long been contested. A systematic review and meta-analysis now consolidates the evidence: DBS modestly worsens some speech dimensions on average — loudness and articulatory precision most consistently — even as it improves limb motor control. Individual outcomes vary considerably, so this is not a reason to avoid DBS, but it strengthens the case for a baseline speech assessment before implantation and an explicit pre-surgical conversation about speech-related expectations. Separately, researchers this month demonstrated that evoked resonant neural activity (ERNA) — an electrical signal that a DBS implant can detect in real time from its own pulses — can be used to automate stimulation programming, reducing the burden of lengthy manual adjustment sessions. This is proof-of-concept work, not yet standard care, but it points toward implants that adapt more continuously with less clinical overhead. Evidence level: meta-analysis (speech); small proof-of-concept study (ERNA automation).

Temporal interference stimulation: non-invasive deep-brain modulation, first human motor data

Temporal interference stimulation (TIS) uses two slightly offset electrical fields applied to the scalp to produce focused stimulation deep in the brain without surgery. A study published this month shows it measurably shifts resting-state connectivity in the motor circuit in people with Parkinson's — a meaningful step beyond the animal and computational modelling that preceded it. The study reports mechanistic changes, not symptom outcomes, so TIS is not yet a treatment to seek out. But it is the kind of early human proof-of-concept that can accelerate trial design quickly. Put it on your watchlist if you are interested in non-surgical, non-pharmacological options further down the pipeline. Evidence level: small human proof-of-concept, mechanistic only.

Alcohol after diagnosis: a consistent symptom-progression signal

Does alcohol consumption after a Parkinson's diagnosis affect how symptoms progress? A dose-response meta-analysis of prospective studies — pooling data across studies and testing for a graduated relationship — finds that higher post-diagnosis intake is associated with faster worsening of both motor and non-motor symptoms. A direct observational study of alcohol use after diagnosis corroborates the direction. The effect size is not dramatic, and observational designs cannot definitively rule out confounding, but the signal is consistent across studies. If your symptoms are progressing faster than expected and you drink regularly, alcohol is a modifiable factor now worth raising explicitly with your neurologist — not as a certainty, but as something the evidence supports discussing. Evidence level: observational, with dose-response meta-analysis.

GBA1-linked Parkinson's: why trials underperform, and what GCase activity signals for cognition

GBA1 gene variants are the most common genetic contributor to Parkinson's, present in a meaningful minority of all patients. Two pieces this month matter for people in this group. First, a clinical commentary argues that trials targeting GBA1-PD have repeatedly failed to show benefit not because the biology is wrong but because they enrol patients whose underlying molecular dysfunction differs substantially — even within GBA1-PD, glucocerebrosidase (GCase, an enzyme involved in cellular recycling) activity and downstream pathology vary enough that a single broad trial arm is too heterogeneous to detect a real signal. If you are enrolled in or considering a GBA1-targeted trial, ask whether the protocol distinguishes between mild and severe GBA1 variants and stratifies by GCase enzyme activity. Second, an observational study links lower GCase activity in blood monocytes (a type of immune cell) to worse cognitive performance and reduced cholinergic (acetylcholine-system) signalling in GBA1-PD — suggesting GCase levels may eventually serve as a biomarker for cognitive risk in this group, though it is not a clinical tool yet. Evidence level: expert opinion/commentary (trial design); observational (cognition and enzyme association).

Non-motor symptoms: mapping which neurotransmitter system is driving yours

Cognitive changes, mood disturbance, and behavioural symptoms can be as disabling as motor problems, yet they are often managed less systematically. A neuroimaging study in early PD maps how disruption across three monoamine systems — dopamine, serotonin, and noradrenaline (the brain's main chemical messaging systems for movement, mood, and alertness respectively) — corresponds to distinct clusters of cognitive and behavioural symptoms. The practical implication is that your specific non-motor symptom profile might reflect which system is most affected, which in turn could help guide pharmacological choices — for example, whether targeting the serotonin system for mood, or noradrenaline for attention, is more likely to help your particular combination of symptoms. This is cross-sectional observational data, not a randomised trial, but it offers a more precise framework for discussing non-motor symptoms with your neurologist rather than treating them as a single undifferentiated category. Evidence level: observational neuroimaging.

On the horizon: toxic alpha-synuclein clusters become detectable

A technical but consequential advance: a commentary on the proximity ligation assay (PLA) describes a method now capable of detecting small, soluble clusters of alpha-synuclein — the protein central to PD pathology — that are invisible to conventional assays. These oligomers (small pre-aggregate clusters, as distinct from the large protein deposits typically measured) are increasingly considered the most neurotoxic form. Being able to detect and quantify them opens the door to their use as endpoints in disease-modifying trials and, eventually, as clinical biomarkers. This is a laboratory advance not yet in clinical use, but it addresses a long-standing measurement gap that has hampered anti-alpha-synuclein therapy development.